Therefore, our results suggest that CD85j, CD45 and CD48 expression represent interesting potential biomarkers in ccRCC and they might constitute possible candidates for immunotherapy whose blockade may result in their validation as novel targets in immuno-oncology. The gene discussed is PTPRC; the disease is nonpapillary renal cell carcinoma.